Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation

AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC ] = 0.08 to 0.27 μM; EC = 0.33 to 1.32 μM) with no significant...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antimicrobial agents and chemotherapy 2018-06, Vol.62 (6)
Hauptverfasser:	Mani, Nagraj, Cole, Andrew G, Phelps, Janet R, Ardzinski, Andrzej, Cobarrubias, Kyle D, Cuconati, Andrea, Dorsey, Bruce D, Evangelista, Ellen, Fan, Kristi, Guo, Fang, Guo, Haitao, Guo, Ju-Tao, Harasym, Troy O, Kadhim, Salam, Kultgen, Steven G, Lee, Amy C H, Li, Alice H L, Long, Quanxin, Majeski, Sara A, Mao, Richeng, McClintock, Kevin D, Reid, Stephen P, Rijnbrand, Rene, Snead, Nicholas M, Micolochick Steuer, Holly M, Stever, Kim, Tang, Sunny, Wang, Xiaohe, Zhao, Qiong, Sofia, Michael J
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents Capsid Hepatitis B Hepatitis B virus Virus Assembly
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!